CLOVIS ONCOLOGY INC (NASDAQ:CLVS)

thumbs up

How Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again

Clovis Oncology Inc. (NASDAQ: CLVS) posted a massive gain of 27% to $23.03 on Tuesday, on the heels of news that the Food and Drug Administration (FDA) had granted it ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Clovis Oncology, Garmin, Lowe’s, NetApp, On Deck, Pioneer Natural, RSP Permian and More

Stocks are very close to all-time highs and futures were indicated marginally higher on Wednesday morning. Investors have proven time after time that they will buy their favorite stocks in ...
Read Full Story »
Female patient on gurney

How Clovis Scored Big on a Milestone FDA Approval

Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares climb late Tuesday after the company announced a key U.S. Food and Drug Administration (FDA) approval. Note that this is the ...
Read Full Story »
FDA_logo

Are Analysts Realistic on Clovis Oncology Now?

Clovis Oncology Inc. (NASDAQ: CLVS) was down about 5% Tuesday and was down even more Wednesday after the Oncologic Drugs Advisory Committee voted against its lung cancer drug. The committee ...
Read Full Story »
hammered

5 Companies That Destroyed Shareholders Last Week

Both the Dow Jones Industrial Average and S&P 500 are now positive for 2016, just in time for the kick off this earnings season. Analysts are expecting some earnings disappointments going ...
Read Full Story »
buy sell stocks

Top Analyst Upgrades and Downgrades: Clovis, CSC, Norfolk Southern, Sprint, Square, Western Digital and More

Stocks traded handily higher on Tuesday and economic data out of China actually was helping out futures again on Wednesday morning. Despite the major selling pressure that was seen in ...
Read Full Story »
Stock Price

The 52-Week Low Club for Tuesday

April 12, 2016: Here are four stocks trading with relatively heavy volume among 17 equities making new 52-week lows in Tuesday's session. The day's NYSE winners led losers by about ...
Read Full Story »
Stock Price

The 52-Week Low Club for Monday

April 11, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday's session. The day's NYSE winners led losers by about ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: GE, 3M, Shopify, SunPower, Zafgen, CIT, Ericsson, Honeywell and Many More

Stocks were looking for a small bounce on Thursday after Wednesday's big sell-off that ended up being less of a big sell-off. Investors have every right to feel jilted in ...
Read Full Story »
Medicine pills

4 Pharmaceutical Stocks With Big Catalysts Pending in 2016

This is going to be a big year in biotech, with a host of drugs set to undergo U.S. Food and Drug Administration (FDA) scrutiny. While picking up an exposure ...
Read Full Story »
biotech word cloud

4 Key FDA Decisions Expected By Year End

Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount ...
Read Full Story »
biotech word cloud

6 BioHealth Movers That Now Cannot Be Ignored

Over the past week, a few biotech companies made absolutely massive runs. In the past year, the health care sector was on fire from positive trials, U.S. Food and Drug ...
Read Full Story »
ThinkstockPhotos-530943067

8 Companies That Destroyed Shareholders Last Week

This past week is being touted as the best week of the S&P 500 for 2015. Still, the stock market is actually a market of stocks, and that love was ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: Antero, Athenahealth, Capstone, Clovis, Genworth, Merck, Nuance, Salesforce and More

Stocks were surprisingly higher on Monday after the weekend's terror attacks in Paris, and in Tuesday's session international markets and U.S. equity futures were also higher. Yet again, we have ...
Read Full Story »
FDA_logo

Clovis More Than Halves on FDA Hurdle

Clovis Oncology Inc. (NASDAQ: CLVS) was leading the bears in Monday’s trading session on news that its lung cancer drug may be delayed. This was announced in the company’s most ...
Read Full Story »